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Erk1/2 pathways, conﬁrming that Cav3 controls TGF-β signalling at the plasmamembrane. Overall, these data
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Caveolae and caveolins play a prominent role to regulate signal
transduction [1–3]. Caveolin-3 (Cav3) is preponderantly expressed in
the skeletal muscle, contributing to proper differentiation of myo-
blasts and homeostasis of myoﬁbers [4–6]. Through its scaffolding
domain, Cav3 interacts with different proteins at the plasma
membrane, thereby inﬂuencing their biological activity, as occurs
for the nitric oxide synthase [7–9], Src tyrosine kinase [10,11], Alk4
and 5 receptors [12] and PI3K-Akt kinases [13–15]. Cav3 expression
must be tightly regulated, as demonstrated by the fact that either a
deﬁciency or an excess causesmuscular disorders. In particular, loss of
Cav3 at the sarcolemma is a feature sign of caveolinopathies, a
heterogeneous group of genetic diseases caused by Cav3 mutations
giving rise to dominant-negative protein forms [16–20]. The missenseCav3 (P104L) substitution is frequently associated to the human limb
girdle muscular dystrophy 1-C (LGMD1C, OMIM #607801) [16], and
its transgenic delivery causes muscular defects also in mice and
zebraﬁsh models [9,12,21]. In addition, even an excess of Cav3 causes
a Duchenne-like muscular phenotype in transgenic mice [22],
deﬁnitely suggesting that Cav3 levels inﬂuence the muscle homeo-
stasis. In the present study we employed immortalized murine
myoblasts to analyse the effects of either Cav3 (P104L) or wild-type
Cav3 delivery on cell fusion, a process that is crucial during embryonal
differentiation or muscle regeneration. We found that both low and
high Cav3 levels affect myoblast fusion. In particular, a more severe
phenotype was conferred by the loss of Cav3, basically correlating
with the attenuation of Akt and p38 activities but also with the
perturbation of TGF-β signalling. In addition, we show that differen-
tiation of myoblasts harbouring the Cav3 (P104L) form was improved
by the administration of IGF-1 or trichostatin A, two molecules
promoting muscle hypertrophy [23,24].2. Materials and methods
2.1. Materials
All the reagents were from Sigma-Aldrich, unless differently
indicated.
Fig. 1.Myoblast fusion is more severely affected by loss rather than excess of Cav3 at the plasmamembrane. C2C12myoblasts were stably transfected with an empty vector (control)
or vectors harbouring either Cav3 (P104L) or wild-type Cav3 (wtCav3) forms. A, after 2 days of differentiation, PCR and Western blot (WB) analyses detected Cav3 transcript and
protein in transfected myoblasts. Under the same conditions, protein content of MyHC was evaluated. B, confocal microscopic images showing that Cav3 was mislocalized to
perinuclear Golgi regions in Cav3 (P104L) myoblasts, as indicated by the merged staining with GM130 marker. In contrast, wtCav3 overexpression produced a labelling
predominantly localized at the plasmamembrane, as observed in control. Bars=100 μm. Graphical panel reporting the average number ofmyotubes observed after differentiation of
control and transfected myoblasts for up to day 2. Myotubes containing two or more nuclei were counted in 10 different microscopic ﬁelds. Data are representative of two
independent experiments.
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Mouse C2C12 and rat L6E9 myoblasts were maintained under
standard conditions (37 °C and 5% CO2 in humidiﬁed incubator) andFig. 2. Cav3 (P104L) expression impairs the differentiation of C2C12 and L6E9myoblasts. Contro
in DM for up to day 4. A, immunoﬂuorescent staining (IF) showing that Cav3 properly loca
accumulated in perinuclear regions without reaching the plasmamembrane, as indicated by th
was morphologically impaired compared to control (Giemsa staining, phase contrast pictures)
and Cav3 (P104L) myoblasts. Results are representative of three independent experiments. Si
MyHC, as detected in control and Cav3 (P104L) myoblasts over a time-course differentiation. Tcultured in a high-serum medium, consisting of high-glucose DMEM
supplemented with 10% or 20% FBS, respectively, in the presence of
100 μg/ml penicillin–streptomycin antibiotic. To induce differentia-
tion, 80% conﬂuent C2C12 or L6E9 myoblasts were switched to a low-l andmyoblasts stably transfectedwithMLC- or CMV-Cav3 (P104L) vectorswere cultured
lized at the plasma membrane in control C2C12 myotubes, whereas in transfected cells
e arrows. Under these conditions, differentiation of MLC- or CMV-Cav3 (P104L) myoblasts
. Bars=100 μm. B, the graphs report the average number of myotubes observed in control
gniﬁcant at pb0.05 (*) or 0.01 (**) vs. control. C, Western blot analyses of myogenin and
ubulin was used as loading control.
Fig. 3. Loss of Cav3, induced by Cav3 (P104L) expression, decreases the activity of Akt and p38 signalling, conferring an immature cell and molecular signature. A, Western blot
analyses of Akt and p38 forms (phosphorylated vs. total), as detected in control and MLC-Cav3 (P104L) myoblasts over a time-course differentiation. Under the same conditions, the
expression of different protein markers was analyzed. Tubulin was used as loading control. B, graphical representation of MyoD, Myf-5 and myogenin transcript levels, obtained by
RT-PCR analysis, as detected in control and MLC-Cav3 (P104L) myoblasts over a time-course differentiation. GAPDH was used to normalize expression. Results are representative of
three independent experiments. Signiﬁcant at pb0.05 (*) vs. control. C, luciferase reporter assays were performed to evaluate the ability of MyoD to transactivate two different
MyoD-responsive promoters, consisting of a MCK promoter or a minimal 4RE element, which were transiently transfected in control C2C12 andMLC-Cav3 (P104L) myoblasts for up
to 24 h in DM. The reporter expression was expressed as the ratio between the activity from Fireﬂy and Renilla luciferase. Results are representative of three independent
experiments. Signiﬁcant at pb0.01 (**) vs. control. D, Western blot analyses of Akt and p38 forms (phosphorylated vs. total), as detected in control and wtCav3-overexpressing
myoblasts after 24 h of differentiation. Tubulin was used as loading control.
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Fig. 4. In C2C12 myoblasts the pharmacological inhibition of both Akt and p38 pathways triggers the molecular signature observed in Cav3 (P104L) myoblasts. A, Western blot
analyses of MyoD, Myf-5 and cyclin D1, as detected in C2C12 cells cultured in DM and daily treated with DMSO (vehicle), SB or LY for up to day 2. Tubulin was used as loading control.
B, phase contrast pictures showing morphology of C2C12 myoblasts cultured in DM in the presence of DMSO or both 5 μM SB and LY for up to day 2. Bars=100 μm. C, Western blot
analyses of MyoD, Myf-5, cyclin D1 and myogenin, as detected in C2C12 cells cultured in DM in the presence of DMSO or both SB and LY inhibitors. Tubulin was used as loading
control. D, in C2C12 cells transiently transfected with a minimal 4-RE element for up to 24 h, the ability of MyoD to transactivate the luciferase reporter was prevented in the
presence of both SB and LY treatment compared to DMSO. Results are representative of three independent experiments. Signiﬁcant at pb0.05 (*) vs. DMSO.
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DMEM supplemented with 2% HS or 1% FBS, respectively. To visualize
myotubular structures, cells were ﬁxed in methanol and stained with
Giemsa reactive. An Image ProPlus software (version 6.2) was used to
quantify the size of myotubes. The average size was calculated as the
mean of 100 samples, as obtained by measuring 10 myotubes in 10
different ﬁelds.
2.3. Plasmids and cell transfections
The plasmids harbouring either the wild-type Cav3 or the Cav3
(P104L) form, under the control of a CMV promoter (pCAGGS vectors),
were kindly provided by Ferruccio Galbiati (University of Pittsburgh,
USA). To allow post-mitotic expression of mutant, Cav-3 (P104L) cDNA
wasexcisedbypCAGGSvectorwithEcoRI restriction enzyme(Promega)
and ligated into a pGEX-KG plasmid; then cDNA was excised again bydouble digestion with SmaI and SacI (Promega), and eventually ligated
into the pMEX vector containing a MLC promoter [25]. Transfections
were carried out by using Lipofectamine 2000 reagent (Invitrogen),
according to manufacturer's instructions. To isolate antibiotic-resistant
clones, C2C12 and L6E9 were cotransfected with pcDNA or pBabe
vectors, and cultured in high-serum medium supplemented with
geneticin (0.5 mg/ml) or puromycin (1 μg/ml), respectively.
2.4. Drug treatments
The pharmacological SB203580 compound (5 μM) was used to
inhibit p38activity,whereas LY294002 (5 μM, aPI3K inhibitor)wasused
to block Akt activity. To induce myotube hypertrophy, IGF-1 (50 ng/ml)
was administered tomyoblasts after 2 days of differentiation, in order to
avoid hyper-proliferative effects [23]. Alternatively, myoblasts were
treated with trichostatin A (TSA), an inhibitor of histone deacetylases,
Fig. 5. Lack of Cav3 perturbs the activation of TGF-β pathways. Western blot analyses of Smad2, Smad3 and Erk1/2 phosphorylation, as detected in control C2C12 and MLC- or CMV-
Cav3 (P104L) myoblasts differentiated for up to day 2, and then left untreated or treated with 5 ng/ml TGF-β for the indicated time-points. Tubulin was used as loading control.
Relative quantiﬁcations are graphically shown. Results are representative of three independent experiments. Signiﬁcant at pb0.05 (*) vs. control.
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size of myotubes [24]. In particular, TSA (50 nM) was administered to
80% conﬂuent cells for up to 16–18 h before addition of DM. Human
recombinant TGF-β (Peprotech) was administered to myoblasts at the
dose of 5 ng/ml.2.5. RNA isolation and semi-quantitative RT-PCR analysis
Total RNA was isolated by Tri-reagent method and digested with
DNase (DNA-free, Ambion). RNA (2 μg) was reverse-transcribed in the
presence of 400 units of MMLV-RT (Promega) and the template was
474 E. Stoppani et al. / Biochimica et Biophysica Acta 1812 (2011) 468–479used for PCR ampliﬁcation. The following forward (F) and reverse (R)
primers (250 nM each) were used:Gene Primers Sequence PCR cycles SizeCav3 F ACCCCAAGAACATCAATGAG 26 310 bp
R TGCAGAAGGTGCGGATACACMyoD F CTGCTCTGATGGCATGATGGATTAC 28 343 bp
R AGAGCACCTGGTAAATCGGATTGGMyf-5 F AGCCCACCAGCCCCACCTC 30 394 bp
R TTCTGCCCAGCTTTTCTTTCCTTCMyogenin F CCAGGAGCCCCACTTCTATGACGGGG 24 590 bp
R TGATGCTGTCCACGATGGACGTAAGGGFollistatin F CTCTTCAAGTGGATGATTTTC 30 334 bp
R ACAGTAGGCATTATTGGTCTGGAPDH F GGTGCTGAGTATGTCGTGGAGTC 21 267 bp
R GGACTGTGGTCATGAGCCCTTCC2.6. Luciferase assays
Gene reporter assays were carried out by using the Promega Dual
Luciferase assay system, according to manufacturer's instructions.
Cells were transiently transfected with vectors harbouring the
reporter gene under the control of a MCK promoter or a four MyoD-
responsive element (4RE) [26,27], in combination with the pRL-
TK-Renilla luciferase control vector to correct the transfection
efﬁciency.2.7. Antibodies
The following primary monoclonal antibodies were used: mouse
anti-Cav3 (clone 26, BD Transduction Laboratories), mouse anti-GM130
(BD Transduction Laboratories), rabbit anti-MyoD (clone M-318, Santa
Cruz Biotechnology), mouse anti-Myf5 (clone C-20, Santa Cruz
Biotechnology), mouse anti-myogenin (clone F5D, Santa Cruz Biotech-
nology), mouse anti-MyHC (Hybridoma Bank, University of Iowa),
rabbit anti-cyclin D1 (clone H295, Santa Cruz Biotechnology), and
mouse anti-alpha-tubulin (clone B-5-1-2, Sigma-Aldrich). Rabbit
polyclonal antibodies from Cell Signaling were used to detect the
phosphorylated Akt (Ser473) and p38 (Thr180/Tyr182) vs. the total forms.
Phosphorylated (Tyr204) vs. total Erk1/2 formswere recognized byusing
mouse monoclonal antibodies from Santa Cruz Biotechnology.2.8. Western blot analysis
Protein concentration was calculated by bicinchoninic acid assay
(Pierce). Equal amounts of protein samples were separated by SDS-
PAGE under reducing conditions and transferred to PVDF membranes.
Incubation with speciﬁc primary antibodies was followed by horserad-
ish peroxidase-conjugated secondary antibodies (Chemicon), and the
immunocomplexes were visualized using enhanced chemilumines-
cence reagent (Chemicon, Cat. number 2600-5). To analyse cyclin D1,
MyoD,Myf-5, myogenin andMyHC, myoblasts were harvested in a cold
RIPA lysis buffer, composed by 20 mM Tris–HCl (pH 7.6), 1% Nonidet
P40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM NaCl, and a mix of
protease inhibitors (Roche Molecular Biochemicals). To analyse Cav3
expression, myoblasts were harvested in a cold Triton lysis buffer,
composed by 10 mM Tris–HCl (pH 8.0), 1% Triton X-100, 5 mM EDTA,
150 mM NaCl and a mix of protease inhibitors. Then cell lysates were
centrifuged (12,000×g for 15 min at 4 °C) and the Triton-insoluble cell
membranous fractions were used for Cav3 analysis. To analyse
phosphorylated vs. total Akt, p38 and Erk1/2 forms, myoblasts were
harvested in a cold lysis buffer composed by 20 mM Tris–HCl (pH 7.4),
0.2% Triton X-100, 1 mMEDTA, 150 mMNaCl, and amix of protease and
phosphatase inhibitors (0.5 mM NaF and Na3VO4).2.9. Immunoﬂuorescence microscopy
C2C12 myoblasts were cultured on 12 mm glass coverslips coated
with 20 μg/ml laminin (Roche). Then cells were ﬁxed with parafor-
maldehyde for 10 min at 37 °C, washed with PBS/sucrose (2%) and
treated with an extraction buffer, composed by 20 mM Hepes
(pH 7.4), 0.5% Triton X-100, 300 mM sucrose, 3 mM MgCl2 and
50 mM NaCl. Subsequently, C2C12 were treated with 3% BSA in PBS
for 15 min, and incubated for 2 h in a humid atmosphere in the
presence of a diluted anti-Cav3 antibody (1:800), anti-GM130
antibody (1:500), or anti-MyHC antibody (1:200). After PBS washing,
samples were incubated for 1 h in the presence of a diluted anti-
mouse or anti-rabbit CY3 conjugated secondary antibody (1:1000,
Jackson Immunoresearch). Cells were visualized by means of a Zeiss
confocal microscope (Carl Zeiss S.p.A.), with the laser set on λ=405–
488–543 nm and the height of the scanning=1 μm. Images (512 ×
512 pixels) were then reconstructed using LSM Image Examiner
software (Carl Zeiss S.p.A.). Alternatively, ﬂuorescent staining was
observed under an Axiovert S100 microscope (Zeiss), and pictures
were takenwith a digital camera (SensiCam) using the Image-Pro Plus
software (version 6.2).
2.10. Statistics
All of the data are expressed as means±S.E. Statistical signiﬁcance
was determined using Student's t analysis. A p value of b0.05 was
considered signiﬁcant.
3. Results
3.1. Cell fusion of immortalized myoblasts is more severely affected by
loss rather than excess of Cav3
Transgenic mice harbouring inactivating Cav3 (P104L) mutation
display loss of Cav3 at the plasmalemma and a severe muscle atrophy
[9,12], whereas mice overexpressing wild-type Cav3 form (wtCav3)
undergo a Duchenne-like muscular phenotype [22], suggesting that
proper levels of Cav3 are crucial for maintaining the muscle
homeostasis. In keeping with these observations, we stably over-
expressed either mutated or wtCav3 form in C2C12 myoblasts to
analyse the effects on the differentiation process. Compared to control
cells delivered with an empty vector, transgene expression produced
a signiﬁcant increase of both Cav3 transcripts (Fig. 1A). However,
whereas transfection of wild-type form produced Cav3 protein
accumulation, Cav3 (P104L) triggered a substantial loss of Cav3
(Fig. 1A). This is consistent with previous observations indicating that
mutated Cav3 proteins display reduced protein half-life and behave
with a dominant-negative fashion, aggregating with the wild-type
forms within the Golgi apparatus, eventually causing loss of Cav3 at
the plasma membrane [19,20]. Confocal microscopy analysis showed
that an antibody for Cav3marked perinuclear regions in Cav3 (P104L)
myoblasts, which were positively co-stained with antibodies for
GM130 [28], a typical Golgi marker (Fig. 1B). On the other side, Cav3
labelling was predominantly localized at the plasma membrane in
wtCav3 overexpressing cells, although the staining displayed a
stronger intensity compared to control myotubes (Fig. 1B). Both of
these conditions (low Cav3 vs. high Cav3 at the plasma membrane)
impaired C2C12 myoblasts differentiation, but besides them, the
presence of Cav3 (P104L) induced a more severe phenotype, as
determined by the analysis of MyHC expression (Fig. 1A) and the
evaluation of morphological differentiation (Fig. 1B). In particular, the
formation of myotubes was almost abolished in the presence of Cav3
(P104L) form (Fig. 1B and graphical panel), likely suggesting that loss
of Cav3, more potently than overexpression, inhibits myoblast fusion.
Since Cav3 expression is physiologically restricted to myoblasts
undergoing differentiation and mature myoﬁbers [4,5], we generated
Fig. 6. IGF-1 or TSA treatments signiﬁcantly improve the differentiation of MLC-Cav3 (P104L) myoblasts. Control and MLC-Cav3 (P104L) myoblasts were cultured in DM, exposed to
TSA or treated with IGF-1 (as described in Materials and methods). A, phase contrast pictures showing the morphology of control and MLC-Cav3 (P104L) myoblasts exposed to the
different treatments for up to day 4. Under the same conditions, immunoﬂuorescence (IF) was performed to stain MyHC and Cav3. Bars=100 μm. B and C, the average number and
area of control and MLC-Cav3 (P104L) myotubes have been quantiﬁed in the absence or presence of IGF-1 and TSA. Results are representative of three independent experiments.
Signiﬁcant at pb0.05 (*) vs. DM. D, upon TSA exposure followed by post-mitotic treatment with IGF-1, MLC-Cav3 (P104L) myotubes developed a giant size, despite being evident the
perinuclear accumulation of Cav3. Bars=100 μm.
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MLC promoter. Expression of MLC-Cav3 (P104L) impaired the
myoblast fusion in both immortalized C2C12 and L6E9 cell linescompared to control (Fig. 2A), despite less severely in comparison
with CMV-Cav3 (P104L), as evidenced by the presence of thin
myotubes (Fig. 2A and B) and a residual MyHC expression (Fig. 2C).
476 E. Stoppani et al. / Biochimica et Biophysica Acta 1812 (2011) 468–479Taken together, these data provide evidence that loss of Cav3 at the
plasma membrane, as induced by Cav3 (P104L) expression, severely
delays the myoblast fusion.
3.2. Cav3 (P104L) imposes an immature molecular signature, dependent
on the attenuation of Akt and p38 signalling networks
We investigated the molecular mechanisms underlying the
defective cell fusion in myoblasts harbouring Cav3 (P104L) form
under the control of MLC promoter. To this purpose, we ﬁrst analysed
the Akt and p38 pathways, as this signalling network is pivotally
involved in the proper coordination of myogenic commitment [29].
Throughout a time-course differentiation, Western blot analyses
detected that the loss of Cav3, induced by mutant expression,
correlated with the decreased levels of phosphorylated Akt and p38
forms compared to control cells (Fig. 3A), leading to an altered
expression pattern of the bHLH transcription factors, such as MyoD,
Myf-5 and myogenin [30,31]. In particular, loss of Cav3 conferred a
molecular signature reminiscent of an immature cell state [32], being
characterized by the decreased levels of MyoD and myogenin and
increased levels of Myf-5 compared to control, as further corroborated
by RT-PCR analysis (Fig. 3B). As conﬁrmed by the luciferase reporter
assays, the ability of MyoD to transactivate a MCK promoter or a
minimal 4RE element [26,27] was effectively impaired in MLC-Cav3
(P104L) cells compared to control (Fig. 3C). In addition, MLC-Cav3
(P104L) myoblasts also displayed a premature cyclin D1 disappear-
ance compared to control (Fig. 3A), an event normally required for the
myogenic commitment [33], but which can also be a consequence of
the PI3K/Akt pathway down-regulation [34,35]. Unlikely observed in
the absence of Cav3, the phosphorylation of Akt and p38 kinases was
not decreased by wtCav3 overexpression (Fig. 3D), suggesting that
lack or excess of Cav3 affects myoblast fusion through different
mechanisms. Subsequently, we aimed to establish whether the
pharmacological inhibition of p38 and Akt activities, as obtained by
respectively administering SB203580 (SB) or LY294002 (LY) com-
pounds, was sufﬁcient to reproduce in control myoblasts the
molecular pattern recognized in MLC-Cav3 (P104L) myoblasts.
Inhibition of either pathway was sufﬁcient to block differentiation
(not shown), leading to down-regulation of MyoD compared to
DMSO-treated cells (Fig. 4A). In the presence of SB, however, cyclin D1
remained elevated, being the activity of p38 required for the proper
cell cycle exit [36], further contributing to maintain elevated Myf-5
levels in comparison with DMSO (Fig. 4A). In the presence of LY, on
the contrary, both Myf-5 and cyclin D1 were down-regulated
compared to DMSO (Fig. 4A), conﬁrming that the sole inhibition of
either pathway affects differentiation but leading to a different
molecular signature. Remarkably, the simultaneous administration
of both SB and LY inhibitors impaired the differentiation of C2C12
myoblasts (Fig. 4B) and decreased the protein content of MyoD, cyclin
D1 and myogenin, leading to sustained Myf-5 levels (Fig. 4C), thus
eliciting the molecular signs observed in MLC-Cav3 (P104L) myo-
blasts. Accordingly, 4RE reporter activity was prevented in C2C12
myoblasts treatedwith SB and LY compared to DMSO, as assayed after a
transient transfection for up to 24 h (Fig. 4D). Overall, these results
indicate that, in our established in vitromodels, loss of Cav3 imposes a
particular immature cell andmolecular signature largely reminiscent of
the simultaneous down-modulation of Akt and p38 signallingnetworks.
3.3. Lack of Cav3 perturbs the activation of TGF-β pathways
It has been shown that, at the plasma membrane, Cav3 physically
interactswith type I TGF-β receptors (termedAlk4andAlk5) to limit the
activity of Smad2 pathway [12]. For this reason, atrophic muscles of
transgenic Cav3 (P104L) mice exhibit increased Smad2 signalling [12].
TGF-β superfamilymembers, such as TGF-β ormyostatin, bind different
speciﬁc type II TGF-β receptors but commonly employ Alk4 or 5receptors to activate Smad-dependent and -independent pathways,
including Smad2, Smad3 and Erk1/2 [37,38]. Activation of TGF-β
pathways exerts an inhibitory effect on the myoblast differentiation,
causing down-regulation of the Akt pathway [39,40], loss of cyclin D1
[34,35], MyoD [41] and myogenin [42], which are the hallmark signs
recognized in MLC-Cav3 (P104L) myoblasts. Thus, we investigated
whether an involvement of the TGF-β pathways might account for the
cell behaviour observed upon Cav3 loss. After 2 days of differentiation,
the basal levels of Erk1/2 phosphorylation appeared slightly but
signiﬁcantly reduced in MLC- and CMV-Cav3 (P104L) myoblasts
compared to control, whereas Smad2 and 3 phosphorylation levels
were unchanged (Fig. 5). Administration of TGF-β rapidly induced the
phosphorylation of Smad2, Smad3 and Erk1/2 in control, while eliciting
a stronger phosphorylation of Smad2, but not Smad3, in Cav3 (P104L)
myoblasts, thus conﬁrming previous in vivo ﬁndings [9]. Consistently,
the TGF-β-induced Erk1/2 phosphorylation was diminished in Cav3
(P104L) myoblasts compared to control (Fig. 5). Taken together, these
data indicate that loss of Cav3 predisposes to over-activation of Smad2
together with down-regulation of Erk1/2 pathways exclusively in the
presence of TGF-β trigger. In addition, these data indirectly suggest that
the attenuation of Akt and p38 signalling, observed in Cav3 (P104L)
myotubes, likely occurs independently on the activation of TGF-β
pathways.
3.4. Stimulation of the Akt and p38 signalling networks, via administration
of IGF-1 or trichostatin A, improves the differentiation of myoblasts even in
the absence of Cav3
We asked whether administration of molecules normally promot-
ing myotube hypertrophy might improve the differentiation of Cav3
(P104L) myoblasts. In particular, we employed IGF-1, a growth factor
exerting an anabolic effect on the skeletal myoﬁbers [23], or
trichostatin A (TSA), an inhibitor of histone deacetylases which
promotes increased cell fusion by raising the expression of follistatin
[24]. Phase contrast pictures and immunoﬂuorescent MyHC staining
indicated that the treatments effectively improved the differentiation
of MLC-Cav3 (P104L)myoblasts, with amore pronounced effect in the
case of TSA treatment (Fig. 6A). Both the treatments did not
signiﬁcantly affect the number of MyHC positive (MyHC+) myotubes
(Fig. 6B), rather their size (Fig. 6C). In MLC-Cav3 (P104L) myoblasts
treated with IGF-1 or TSA, Cav3 clearly remained mislocalized to the
Golgi apparatus and a recovery at the plasma membrane was not
observed (Fig. 6A). Interestingly, exposure of MLC-Cav3 (P104L)
myoblasts to TSA, followed by post-mitotic IGF-1 treatment, elicited
the formation of giant myotubes, featured by an intense perinuclear
Cav3 staining (Fig. 6D), thus conﬁrming the ability of these cells to
increase their size regardless of the improper Cav3 localization. As
evaluated at transcript levels, TSA was effectively able to raise the
follistatin expression in both MLC-Cav3 (P104L) myoblasts and
control cells (Fig. 7A) [24]. In the presence of IGF-1 or TSA, Western
blot analyses showed that the phosphorylation of both Akt and p38
kinases was partially re-enabled in MLC-Cav3 (P104L) myoblasts
(Fig. 7B). Thus, the treatments produced a rescue of MyoD and
myogenin levels and elicited a gradual Myf-5 disappearing in MLC-
Cav3 (P104L) myoblasts (Fig. 7C), leading to a recovery of MyHC
during the differentiation (Fig. 7D). Taken together, these results
indicate that both IGF-1 and the histone deacetylase inhibitor TSA are
effective to enhance differentiation in myoblasts harbouring Cav3
(P104L) form.
4. Discussion
Cav3 represents a ﬁrst-line checkpoint for the regulation of cell
signalling in muscle cells [1–3]. By functionally interacting at the
plasma membrane with several protein partners, Cav3 inﬂuences an
array of biological functions, thus conﬁguring as a membrane sensor.
Fig. 7. IGF-1 or TSA treatments, by enabling Akt and p38 signalling, restore the expression ofmyogenicmarkers in Cav3 (P104L) myotubes. A, follistatin levels weremonitored by RT-PCR
analysis in control and MLC-Cav3 (P104L) myoblasts, after treatment with DMSO or TSA and subsequent exposure to DM for up to 24 h. GAPDH was used to normalize expression.
B,Western blot analyses of the Akt and p38 forms (phosphorylated vs. total), as detected in control andMLC-Cav3 (P104L) cells subjected to IGF-1 fromday 2 to day 3, or exposed to TSA.
Tubulin was used as loading control. C, Western blot analyses of MyoD, Myf-5 and myogenin, as detected in control and MLC-Cav3 (P104L) myoblasts cultured in DM, exposed to TSA or
post-mitotically treatedwith IGF-1 for the indicated time-points. Tubulinwas used as loading control. Numbers below the panels indicate the protein quantiﬁcation, calculated as the ratio
between each band protein and the respective tubulin. D, upon the same treatments seen above, Western blot analyses detected the levels of MyHC in control and MLC-Cav3 (P104L)
myotubes after 4 days of differentiation. Tubulin was used as loading control.
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clearly suggested that balanced levels of Cav3 are required to
maintain the muscle homeostasis, as both its lack and excess
compromise the integrity of skeletal muscle apparatus
[12,15,21,22,43]. In addition, previous works have shown that loss
of Cav3 inhibits myoblast differentiation [44,45] or causes death of
cultured muscle cells [46]. In the present study we provide evidence
that both lack and overexpression of Cav3 affect the in vitro process of
myoblast fusion, thus conﬁrming previous in vivo ﬁndings. Neverthe-
less, loss of Cav3 induced by Cav3 (P104L) form, but not the
overexpression, elicited an immature cell and molecular signature
due to the simultaneous attenuation of both Akt and p38 MAPK
pathways, the main signalling networks by which the autocrine/
paracrine extracellular cues signal into myoblasts to drive the fusion
process [29,47–50]. In support of this evidence, a previous work
showed that a down-regulation of both Akt and p38 pathways occurs
in Cav3 null myoblasts, leading to reduced insulin-stimulated glucose
uptake [14]. Interestingly, Cav3 synthesis increases during differen-
tiation of muscle cells quite dependently on the activation of both Akt
and p38 pathways [44,45], suggesting that its localization at the
plasma membrane might further provide a positive loop for the
regulation of this signalling network. In this perspective, Cav3
conﬁgures as a key player of the myoblast fusion, and, accordingly,
it has been recently shown that disruption of focal adhesion kinase
signalling impairs myoblast fusion leading to selective down-
regulation of Cav3 [51]. While a close link between Cav3 and Akt
kinase activity has been already demonstrated [13–15], the potential
relationship with p38 should be taken into account, being the
activation of this pathway pivotally involved in the process of
myoblast fusion upon N-cadherin ligation and the subsequent
recruitment of the multifunctional cell surface Cdo protein [52,53].
Another point of interest in this work concerned the investigation of
TGF-β signalling, being this pathway involved in themuscular atrophy
of transgenic Cav3 (P104L) mice [12]. Our results suggest that, in
cultured myotubes, loss of Cav3 was per se not sufﬁcient to perturb
TGF-β pathways, indicating that the attenuation of Akt and p38
pathways occurred independently on TGF-β signalling to promote the
failure of myogenic program. Interestingly, Cav3 (P104L) myotubes
treated with TGF-β displayed the over-activation of Smad2 pathway
together with a down-modulation of Erk1/2 pathway, suggesting that
the combination of these events, rather than the sole over-activation
of Smad2 [12], might contribute to affect the integrity of myoﬁbers.
Remarkably, differentiation of Cav3 (P104L) myotubes was improved
by the treatment with IGF-1 or TSA [23,24] as effect of Akt and p38
reactivation and apparently regardless of the lack of Cav3 recovery at
the plasma membrane. These results indicate that if Cav3 is not
strictly essential for the Akt and p38 signalling, it might rather serve to
facilitate or change the outcome of its activation, thus working as a
sensor. These data also suggest that the contribution of molecules
sustaining Akt and p38 activities might partially counter the damages
in Cav3-deﬁcient muscles. Finally, another interesting feature which
should be taken in account concerns the ability of a mutated caveolin-
1 (P132L) form, the mutation ortholog to Cav3 (P104L), to confer an
immature signature to human breast cancerous cells, leading to
increased invasiveness and metastatic potential [54]. In keeping with
these ﬁndings, we hypothesize that the Cav3 (P104L) form might
behave with a similar fashion in skeletal muscle, imposing an
immature cell and molecular signature by limiting the activity of
Akt and p38 signalling networks.Author's statement
The authors declare that thematerial includes an original research,
which has not been previously published and has not been submitted
for publication elsewhere while under consideration.Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
WethankPier Lorenzo Puri (TelethonDulbecco Institute, Rome, Italy)
for providing the MCK and 4RE reporter vectors and Stefano Pianta for
providing GM130 antibody. This work was supported by Associazione
Amici per il Cuore-ONLUS, Chiari (BS)-Italy to A.F. and E.M., by
Fondazione Cariplo grant to E.M. and by University of Brescia research
fund (ex 60%) to A.F.
References
[1] R.G. Parton, K. Simons, The multiple faces of caveolae, Nat. Rev. Mol. Cell Biol.
8 (2007) 185–194.
[2] H.H. Patel, F. Murray, P.A. Insel, Caveolae as organizers of pharmacologically
relevant signal transduction molecules, Annu. Rev. Pharmacol. Toxicol. 48
(2008) 359–391.
[3] T.M.Williams, M.P. Lisanti, The caveolin genes: from cell biology tomedicine, Ann.
Med. 36 (2004) 584–895.
[4] M. Way, R.G. Parton, M-caveolin, a muscle-speciﬁc caveolin-related protein, FEBS
Lett. 378 (1996) 108–112.
[5] Z. Tang, P.E. Scherer, T. Okamoto, K. Song, C. Chu, D.S. Kohtz, I. Nishimoto, H.F. Lodish,
M.P. Lisanti, Molecular cloning of caveolin-3, a novel member of the caveolin gene
family expressed predominantly in muscle, J. Biol. Chem. 271 (1996) 2255–2261.
[6] R. Hnasko, M.P. Lisanti, The biology of caveolae: lessons from caveolin knockout
mice and implications for human disease, Mol. Interv. 3 (2003) 445–464.
[7] V.J. Venema, H. Ju, R. Zou, R.C. Venema, Interaction of neuronal nitric-oxide
synthase with caveolin-3 in skeletal muscle. Identiﬁcation of a novel caveolin
scaffolding/inhibitory domain, J. Biol. Chem. 272 (1997) 28187–28190.
[8] G. García-Cardeña, P. Martasek, B.S. Masters, P.M. Skidd, J. Couet, S. Li, M.P. Lisanti,
W.C. Sessa, Dissecting the interaction between nitric oxide synthase (NOS) and
caveolin. Functional signiﬁcance of the nos caveolin binding domain in vivo, J.
Biol. Chem. 272 (1997) 25437–25440.
[9] Y. Sunada, H. Ohi, A. Hase, H. Ohi, T. Hosono, S. Arata, S. Higuchi, K. Matsumura, T.
Shimizu, Transgenic mice expressing mutant caveolin-3 show severe myopathy
associated with increased nNOS activity, Hum. Mol. Genet. 10 (2001) 173–178.
[10] S. Li, J. Couet, M.P. Lisanti, Src tyrosine kinases, Ga subunits, and H-Ras share
a common membrane-anchored scaffolding protein, caveolin. Caveolin
binding negatively regulates the auto-activation of Src tyrosine kinases, J. Biol.
Chem. 271 (1996) 29182–29190.
[11] G.M. Smythe, J.C. Eby, M.H. Disatnik, T.A. Rando, A caveolin-3 mutant that causes
limb girdle muscular dystrophy type 1 C disrupts Src localization and activity and
induces apoptosis in skeletal myotubes, J. Cell Sci. 116 (2003) 4739–4749.
[12] Y. Ohsawa, H. Hagiwara, M. Nakatani, A. Yasue, K. Moriyama, T. Murakami, K.
Tsuchida, S. Noji, Y. Sunada, Muscular atrophy of caveolin-3-deﬁcient mice is
rescued by myostatin inhibition, J. Clin. Invest. 116 (2006) 2924–2934.
[13] J. Oshikawa, K. Otsu, Y. Toya, T. Tsunematsu, R. Hankins, J. Kawabe, S. Minamisawa,
S. Umemura, Y. Hagiwara, Y. Ishikawa, Insulin resistance in skeletal muscles of
caveolin-3-null mice, Proc. Natl Acad. Sci. USA 101 (2004) 12670–12675.
[14] K. Fecchi, D. Volonte, M.P. Hezel, K. Schmeck, F. Galbiati, Spatial and temporal
regulation of GLUT4 translocation by ﬂotillin-1 and caveolin-3 in skeletal muscle
cells, FASEB J. 20 (2006) 705–707.
[15] F. Capozza, T.P. Combs, A.W. Cohen, Y.R. Cho, S.Y. Park, W. Schubert, T.M.Williams,
D.L. Brasaemle, L.A. Jelicks, P.E. Scherer, J.K. Kim, M.P. Lisanti, Caveolin-3 knockout
mice show increased adiposity and whole body insulin resistance, with ligand-
induced insulin receptor instability in skeletal muscle, Am. J. Physiol. Cell Physiol.
288 (2005) C1317–C1331.
[16] C. Minetti, F. Sotgia, C. Bruno, P. Scartezzini, P. Broda, M. Bado, E. Masetti, P.
Mazzocco, A. Egeo, M.A. Donati, D. Volonté, F. Galbiati, G. Cordone, F.D. Bricarelli,
M.P. Lisanti, F. Zara, Mutations in the caveolin-3 gene cause autosomal dominant
limb-girdle muscular dystrophy, Nat. Genet. 18 (1998) 365–368.
[17] S.E. Woodman, F. Sotgia, F. Galbiati, C. Minetti, M.P. Lisanti, Caveolinopathies:
mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases,
Neurology 62 (2004) 538–543.
[18] E. Gazzerro, F. Sotgia, C. Bruno, M.P. Lisanti, C. Minetti, Caveolinopathies: from the
biology of caveolin-3 to human diseases, Eur. J. Hum. Genet. 18 (2010) 137–145.
[19] F. Galbiati, D. Volonte, C. Minetti, J.B. Chu, M.P. Lisanti, Phenotypic behavior of
caveolin-3 mutations that cause autosomal dominant limb girdle muscular
dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the
Golgi complex, J. Biol. Chem. 274 (1999) 25632–25641.
[20] F. Galbiati, D. Volonte, C. Minetti, D.B. Bregman, M.P. Lisanti, Limb-girdle muscular
dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and
proteasomal degradation, J. Biol. Chem. 275 (2000) 37702–37711.
[21] S.J. Nixon, J. Wegner, C. Ferguson, P.F. Mery, J.F. Hancock, P.D. Currie, B. Key, M.
Westerﬁeld, R.G. Parton, Zebraﬁsh as a model for caveolin-associated muscle
disease; caveolin-3 is required for myoﬁbril organization and muscle cell
patterning, Hum. Mol. Genet. 14 (2005) 1727–1743.
[22] F. Galbiati, D. Volonte, J.B. Chu, M. Li, S.W. Fine, M. Fu, J. Bermudez, M. Pedemonte,
K.M. Weidenheim, R.G. Pestell, C. Minetti, M.P. Lisanti, Transgenic overexpression
479E. Stoppani et al. / Biochimica et Biophysica Acta 1812 (2011) 468–479of caveolin-3 in skeletal muscle ﬁbers induces a Duchenne-like muscular
dystrophy phenotype, Proc. Natl Acad. Sci. USA 97 (2000) 9689–9694.
[23] A.Musarò,N.Rosenthal,Maturationof themyogenicprogramis inducedbypostmitotic
expression of insulin-like growth factor I, Mol. Cell. Biol. 19 (1999) 3115–3124.
[24] S. Iezzi, M. Di Padova, C. Serra, G. Caretti, C. Simone, E. Maklan, G. Minetti, P. Zhao,
E.P. Hoffman, P.L. Puri, V. Sartorelli, Deacetylase inhibitors increase muscle cell
size by promoting myoblast recruitment and fusion through induction of
follistatin, Dev. Cell 6 (2004) 673–684.
[25] N. Rosenthal, J.M. Kornhauser, M. Donoghue, K.M. Rosen, J.P. Merlie, Myosin light
chain enhancer activates muscle-speciﬁc, developmentally regulated gene
expression in transgenic mice, Proc. Natl Acad. Sci. USA 86 (1989) 7780–7784.
[26] P.L. Puri, M.L. Avantaggiati, C. Balsano, N. Sang, A. Graessmann, A. Giordano, M.
Levrero, p300 is required for MyoD-dependent cell cycle arrest and muscle-
speciﬁc gene transcription, EMBO J. 16 (1997) 369–383.
[27] V. Sartorelli, J. Huang, Y. Hamamori, L. Kedes, Molecular mechanisms of myogenic
coactivation by p300: direct interaction with the activation domain of MyoD and
with the MADS box of MEF2C, Mol. Cell. Biol. 17 (1997) 1010–1026.
[28] N. Nakamura, C. Rabouille, R. Watson, T. Nilsson, N. Hui, P. Slusarewicz, T.E. Kreis,
G. Warren, Characterization of a cis-Golgi matrix protein, GM130, J. Cell Biol. 131
(1995) 1715–1726.
[29] Y. Li, B. Jiang, W.Y. Ensign, P.K. Vogt, J. Han, Myogenic differentiation requires
signalling through both phosphatidylinositol 3-kinase and p38 MAP kinase, Cell.
Signal. 12 (2000) 751–757.
[30] C.A. Berkes, S.J. Tapscott, MyoD and the transcriptional control of myogenesis,
Semin. Cell Dev. Biol. 16 (2005) 585–595.
[31] F. Le Grand, M.A. Rudnicki, Skeletal muscle satellite cells and adult myogenesis,
Curr. Opin. Cell Biol. 19 (2007) 628–633.
[32] Z. Yablonka-Reuveni, M.A. Rudnicki, A.J. Rivera, M. Primig, J.E. Anderson, P.
Natanson, The transition from proliferation to differentiation is delayed in
satellite cells from mice lacking MyoD, Dev. Biol. 210 (1999) 440–455.
[33] J.M. Dahlman, J. Wang, N. Bakkar, D.C. Guttridge, The RelA/p65 subunit of NF-
kappaB speciﬁcally regulates cyclin D1 protein stability: implications for cell cycle
withdrawal and skeletal myogenesis, J. Cell. Biochem. 106 (2009) 42–51.
[34] W. Yang, Y. Zhang, Y. Li, Z. Wu, D. Zhu, Myostatin induces cyclin D1 degradation to
cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta
pathway and is antagonized by insulin-like growth factor 1, J. Biol. Chem. 282
(2007) 3799–3808.
[35] M. Ji, Q. Zhang, J. Ye, X. Wang, W. Yang, D. Zhu, Myostatin induces p300
degradation to silence cyclin D1 expression through the PI3K/PTEN/Akt pathway,
Cell. Signal. 20 (2008) 1452–1458.
[36] E. Perdiguero, V. Ruiz-Bonilla, L. Gresh, L. Hui, E. Ballestar, P. Sousa-Victor, B.
Baeza-Raja, M. Jardí, A. Bosch-Comas, M. Esteller, C. Caelles, A.L. Serrano, E.F.
Wagner, P. Muñoz-Cánoves, Genetic analysis of p38 MAP kinases in myogenesis:
fundamental role of p38alpha in abrogating myoblast proliferation, EMBO J. 26
(2007) 1245–1256.
[37] R. Derynck, Y.E. Zhang, Smad-dependent and Smad-independent pathways in
TGF-beta family signalling, Nature 425 (2003) 577–584.
[38] J. Massaguè, R.R. Gomis, The logic of TGFbeta signaling, FEBS Lett. 580 (2006)
2811–2820.
[39] A.U. Trendelenburg, A. Meyer, D. Rohner, J. Boyle, S. Hatakeyama, D.J. Glass,
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentia-
tion and myotube size, Am. J. Physiol. Cell Physiol. 296 (2009) C1258–C1270.[40] M.R. Morissette, S.A. Cook, C. Buranasombati, M.A. Rosenberg, A. Rosenzweig,
Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt, Am. J.
Physiol. Cell Physiol. 297 (2009) C1124–C1132.
[41] B. Langley, M. Thomas, A. Bishop, M. Sharma, S. Gilmour, R. Kambadur, Myostatin
inhibits myoblast differentiation by down-regulating MyoD expression, J. Biol.
Chem. 277 (2002) 49831–49840.
[42] D. Joulia, H. Bernardi, V. Garandel, F. Rabenoelina, B. Vernus, G. Cabello,
Mechanisms involved in the inhibition of myoblast proliferation and differenti-
ation by myostatin, Exp. Cell Res. 286 (2003) 263–275.
[43] F. Galbiati, J.A. Engelman, D. Volonte, X.L. Zhang, C. Minetti, M. Li, H.J. Hou, B.
Kneitz, W. Edelmann, M.P. Lisanti, Caveolin-3 null mice show a loss of caveolae,
changes in themicrodomain distribution of the dystrophin-glycoprotein complex,
and t-tubule abnormalities, J. Biol. Chem. 276 (2001) 21425–21433.
[44] F. Galbiati, D. Volonte, J.A. Engelman, P.E. Scherer, M.P. Lisanti, Targeted down-
regulation of caveolin-3 is sufﬁcient to inhibit myotube formation in differenti-
ating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein
kinase is required for induction of caveolin-3 expression and subsequent myotube
formation, J. Biol. Chem. 274 (1999) 30315–30321.
[45] A. Fanzani, E. Stoppani, L. Gualandi, R. Giuliani, F. Galbiati, S. Rossi, A. Fra, A. Preti,
S. Marchesini, Phenotypic behavior of C2C12 myoblasts upon expression of the
dystrophy-related caveolin-3 P104L and TFT mutants, FEBS Lett. 581 (2007)
5099–5104.
[46] G.M. Smythe, T.A. Rando, Altered caveolin-3 expression disrupts PI(3) kinase signaling
leading to death of cultured muscle cells, Exp. Cell Res. 312 (2006) 2816–2825.
[47] C. Rommel, S.C. Bodine, B.A. Clarke, R. Rossman, L. Nunez, T.N. Stitt, G.D.
Yancopoulos, D.J. Glass, Mediation of IGF-1-induced skeletal myotube hyper-
trophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways, Nat. Cell Biol. 11
(2001) 1009–1013.
[48] A. Zetser, E. Gredinger, E. Bengal, p38 mitogen-activated protein kinase pathway
promotes skeletal muscle differentiation. Participation of the Mef2c transcription
factor, J. Biol. Chem. 274 (1999) 5193–5200.
[49] Z. Wu, P.J. Woodring, K.S. Bhakta, K. Tamura, F. Wen, J.R. Feramisco, M. Karin, J.Y.
Wang, P.L. Puri, p38 and extracellular signal-regulated kinases regulate the
myogenic program at multiple steps, Mol. Cell. Biol. 20 (2000) 3951–3964.
[50] C. Serra, D. Palacios, C. Mozzetta, S.V. Forcales, I. Morantte, M. Ripani, D.R. Jones, K.
Du, U.S. Jhala, C. Simone, P.L. Puri, Functional interdependence at the chromatin
level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle
differentiation, Mol. Cell 28 (2007) 200–213.
[51] N.L. Quach, S. Biressi, L.F. Reichardt, C. Keller, T.A. Rando, Focal adhesion kinase
signaling regulates the expression of caveolin 3 and beta1 integrin, genes essential
for normal myoblast fusion, Mol. Biol. Cell 20 (2009) 3422–3435.
[52] G. Takaesu, J.S. Kang, G.U. Bae, M.J. Yi, C.M. Lee, E.P. Reddy, R.S. Krauss, Activation
of p38alpha/beta MAPK in myogenesis via binding of the scaffold protein JLP to
the cell surface protein Cdo, J. Cell Biol. 175 (2006) 383–388.
[53] M. Lu, R.S. Krauss, N-cadherin ligation, but not Sonic hedgehog binding, initiates
Cdo-dependent p38alpha/beta MAPK signaling in skeletal myoblasts, Proc. Natl
Acad. Sci. USA 107 (2010) 4212–4217.
[54] G. Bonuccelli, M.C. Casimiro, F. Sotgia, C. Wang, M. Liu, S. Katiyar, J. Zhou, E. Dew, F.
Capozza,K.M.Daumer,C.Minetti, J.N.Milliman, F.Alpy,M.C.Rio, C. Tomasetto, I.Mercier,
N. Flomenberg, P.G. Frank, R.G. Pestell, M.P. Lisanti, Caveolin-1 (P132L), a common
breast cancer mutation, confers mammary cell invasiveness and deﬁnes a novel stem
cell/metastasis-associated gene signature, Am. J. Pathol. 174 (2009) 1650–1662.
